TGTX TG Therapeutics (TGTX) Q2 FY26 earnings call
TG Therapeutics delivered another strong quarter, driven by robust commercial execution for BRIUMVI, which continues to exceed expectations and is on track for a $1 billion annualized run rate. The company is also advancing its pipeline with positive ENHANCE data for a simplified IV initiation and progress on a subcutaneous formulation, while expanding into new autoimmune indications and advancing its CAR-T program. This quarter marks an important evolution, positioning BRIUMVI as a durable engine for broader innovation and value creation.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.